HomeAbout

TL;DR CNBC


Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs - TL;DR CNBC

Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs

Publishing timestamp: 2023-11-30 17:26:15


Summary

Novo Nordisk has sued two compounding pharmacies in Florida for allegedly selling impure and potentially unsafe drugs claiming to contain semaglutide, the active ingredient in their weight loss treatment Wegovy and diabetes medication Ozempic. The Danish drugmaker is facing shortages of these drugs in the U.S. due to high demand. Novo Nordisk is seeking to prevent the pharmacies from selling their products and is raising concerns about the safety risks posed by unknown impurities in the drugs. This is part of a larger legal action by Novo Nordisk against compounding pharmacies selling knockoffs of their drugs.


Sentiment: NEGATIVE

Tickers: LLYNOVO.B-DK

Keywords: health care industrybiotech and pharmaceuticalsnovo nordisk a/sbusinesseli lilly and cobusiness newspharmaceuticalsbiotechnologyproducts and services

Source: https://www.cnbc.com/2023/11/30/novo-nordisk-sues-pharmacies-over-impure-wegovy-ozempic-dupes.html


Developed by Leo Phan